Bicycle Therapeutics plc. (BCYC) recently unveiled updated Phase 1/2 clinical trial outcomes for multiple candidate drugs targeting various advanced cancers. These include:1. **Zelenectide pevedotin** (formerly BT8009) for metastatic urothelial cancer (mUC),2. **BT5528** for advanced solid tumors such as mUC and ovarian cancer, and3. **BT7480**, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA), for advanced solid tumors.Additionally, the company provided insights into peripheral neuropathy, a significant adverse event linked to monomethyl auristatin E (MMAE)-based drug conjugates, as observed in patients treated with BTC molecules.The detailed findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.### Key Highlights#### Zelenectide Pevedotin in Metastatic Urothelial Cancer (mUC):- **Overall Response Rate (ORR)**: 45%- **Median Duration of Response**: 11.1 months- **Safety Profile**: Generally well-tolerated#### BT5528 in Advanced Solid Tumors:- In patients with advanced solid tumors, particularly in the 6.5 mg/m² cohort treated every two weeks, BT5528 demonstrated:- **Overall Response Rate (ORR)**: 45%- **Emerging Differentiated Safety Profile**: Indicating consistent antitumor activity#### Safety and Tolerability:- Both zelenectide pevedotin and BT5528 exhibited a relatively low incidence and severity of treatment-related peripheral neuropathy. This allowed the majority of patients to continue with their respective therapies unaltered.#### BT7480 in Advanced Nectin-4-Associated Solid Tumors:- Showcased a favorable safety profile.- Indicated preliminary antitumor activity.These results highlight the potential of Bicycle Therapeutics’ innovative therapies in addressing significant unmet needs in oncology.The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
